CliffBio
small molecule

CONTEPO

FOSFOMYCIN DISODIUM

Loss of exclusivityJanuary 2039latest FDA-listed patent expiry
CompanyMeitheal Pharmaceuticals, Inc. →View the full company profile on CliffBio

Drug detail

Brand nameCONTEPO
Active ingredientFOSFOMYCIN DISODIUM
StrengthEQ 6GM BASE/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalOctober 2025
Marketing statusRX

Listed patents

PatentExpiresType
11541064January 2039use U-4331
9345717October 2034use U-4332
10086006October 2034use U-4332

Regulatory exclusivity

CodeExpires
GAINOctober 2033
NPOctober 2028

More from Meitheal Pharmaceuticals, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

CONTEPO patent cliff — loss of exclusivity January 2039 | CliffBio